Senti Biosciences (SNTI) to Release Quarterly Earnings on Thursday

Senti Biosciences (NASDAQ:SNTI) is expected to be releasing its Q3 2025 results before the market opens on Thursday, November 13th. Analysts expect Senti Biosciences to post earnings of ($0.59) per share for the quarter. Parties can check the company’s upcoming Q3 2025 earningsummary page for the latest details on the call scheduled for Thursday, November 13, 2025 at 4:00 PM ET.

Senti Biosciences (NASDAQ:SNTI) last released its earnings results on Thursday, August 7th. The company reported ($0.56) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.58) by $0.02. The business had revenue of $0.50 million during the quarter, compared to analysts’ expectations of $1.30 million. On average, analysts expect Senti Biosciences to post $-15 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Senti Biosciences Stock Up 7.2%

Shares of Senti Biosciences stock opened at $1.94 on Thursday. Senti Biosciences has a 12 month low of $1.26 and a 12 month high of $16.94. The stock has a market cap of $50.75 million, a PE ratio of -0.22 and a beta of 2.09. The business has a fifty day simple moving average of $1.68 and a 200-day simple moving average of $2.24.

Analyst Upgrades and Downgrades

Several research firms recently commented on SNTI. Weiss Ratings restated a “sell (e+)” rating on shares of Senti Biosciences in a report on Wednesday, October 8th. Wall Street Zen upgraded Senti Biosciences from a “sell” rating to a “hold” rating in a report on Monday, August 18th. Chardan Capital reissued a “buy” rating and set a $12.00 price objective on shares of Senti Biosciences in a research report on Friday, August 8th. Finally, HC Wainwright assumed coverage on Senti Biosciences in a research report on Tuesday, October 14th. They issued a “buy” rating and a $12.00 target price on the stock. Three investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Senti Biosciences presently has a consensus rating of “Moderate Buy” and a consensus target price of $9.67.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Senti Biosciences stock. Armistice Capital LLC bought a new position in shares of Senti Biosciences, Inc. (NASDAQ:SNTI) during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund bought 892,207 shares of the company’s stock, valued at approximately $1,883,000. Armistice Capital LLC owned 3.41% of Senti Biosciences at the end of the most recent quarter. 25.70% of the stock is currently owned by institutional investors and hedge funds.

Senti Biosciences Company Profile

Senti Biosciences, Inc operates as a preclinical biotechnology company that develops next-generation cell and gene therapies engineered with its gene circuit platform technologies for various diseases. Its lead product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications.